

# The SIGMA Consortium (SIGMA)

**First published:** 10/02/2013

**Last updated:** 16/12/2024

Network

## Network identification

### Network ID

45592

---

### Network countries

- ☐ Denmark
  - ☐ European Union
  - ☐ France
  - ☐ Germany
  - ☐ Italy
  - ☐ Netherlands
  - ☐ Norway
  - ☐ Spain
  - ☐ Sweden
  - ☐ United Kingdom
- 

### Network website

<https://www.sigmaconsortium.eu>

---

## ENCePP partner

Yes

## Network description

The SIGMA Consortium is a hub for the design, contracting, execution, delivery and interpretation of European pharmacoepidemiologic and real-world evidence (PE/RWE) studies, providing a one-stop shop for entities that require research services. The SIGMA Consortium's VISION is to provide best evidence on the use, benefits and harms of medications, vaccines and devices for the betterment of public health and patient care. Its MISSION is to provide trusted PE/RWE research through a European federated professional network of excellence based on the ENCePP Code of Conduct. The SIGMA Office, co-led by staff from RTI-HS and PHARMO Institute, runs the day-to-day activities of the Consortium for research requests. Each request is distributed to all SIGMA members, who express interest and availability to participate in the study in the role(s) of Coordinating Centre, Principal Investigator Centre and/or Research Site. Study funders can contact the SIGMA Office at [info@sigmaconsortium.eu](mailto:info@sigmaconsortium.eu).

## Network details

### **Network primary therapeutic area:**

- Anaesthesia
- Cardiovascular diseases
- Congenital Malformations
- Disorders of the central nervous system
- Ear nose and oropharynx disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal tract

- Geriatrics
  - Gynaecology
  - Immunological products and vaccines
  - Immunosuppression
  - Infectious diseases
  - Liver disease
  - Malignant disease
  - Medical devices
  - Musculoskeletal and joint diseases
  - Neonatology
  - Nutrition and blood
  - Osteoporosis
  - Paediatrics
  - Poisoning/Overdose
  - Pregnancy
  - Psychiatry
  - Renal impairment
  - Respiratory diseases
  - Skin disorders
  - Urinary tract disorders
- 

### **Network funding:**

- • EU institutional research programme
- • Non-for-profit organisation (e.g. charity)
- • Other
- • Pharmaceutical company and other private sector

## Contact

Carla Franzoni & Josine Kuiper [info@sigmaconsortium.eu](mailto:info@sigmaconsortium.eu)

**Main**

[info@sigmaconsortium.eu](mailto:info@sigmaconsortium.eu)

Susana Perez-Gutthann [info@sigmaconsortium.eu](mailto:info@sigmaconsortium.eu)

**Alternate**

[info@sigmaconsortium.eu](mailto:info@sigmaconsortium.eu)